Coronavirus Covid-19 Information

AcceleRET-Lung / BO42864 (formerly BLU-667-2303)

A Randomized, Open-Label, Phase 3 Study of Pralsetinib Versus Standard of Care Plt-based Chemotherapy for First Line RET Fusion-positive, Metastatic Non-Small Cell Lung Cancer
Study Phase: Phase 3
Principal Investigator: Dr Sinead Cuffe
Further information

BMS CA 209-73L

A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer
Study Phase: Phase 3
Principal Investigator: Dr Sinead Cuffe
Further information

M14-239

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
Study Phase: Phase 2
Principal Investigator: Dr Sinead Cuffe
Further information

ZEAL-1L

A Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants with Advanced/Metastatic Non-Small Cell Lung Cancer.
Study Phase: Phase 3
Principal Investigator: Dr Sinead Cuffe
Further information

Enquire about a Cancer Clinical Trial

If you would like more information on Cancer Clinical Trials you can contact us.

Make an enquiry